Debio 0617B manufacturers
- Debio 0617B
-
- $1520.00 / 25mg
-
2025-10-27
- CAS:1332329-27-7
- Min. Order:
- Purity:
- Supply Ability: 10g
|
| | Debio 0617B Basic information |
| Product Name: | Debio 0617B | | Synonyms: | Debio 0617B;DEBIO0617B;DEBIO-0617B;4-trifluoromethyl-pyridine-2-carboxylic acid {4-chloro-3-[2-(4-methylcarbamoyl-phenylamino)-7,8-dihydro-5H-pyrido[4,3-d]pyrimidin-6-yl]-phenyl}-amide;2-Pyridinecarboxamide, N-[4-chloro-3-[7,8-dihydro-2-[[4-[(methylamino)carbonyl]phenyl]amino]pyrido[4,3-d]pyrimidin-6(5H)-yl]phenyl]-4-(trifluoromethyl)-;Jak/Src Inhibitor 1 . hydrochloride | | CAS: | 1332329-27-7 | | MF: | C28H23ClF3N7O2 | | MW: | 581.98 | | EINECS: | | | Product Categories: | | | Mol File: | 1332329-27-7.mol |  |
| | Debio 0617B Chemical Properties |
| density | 1.448±0.06 g/cm3(Predicted) | | pka | 10.07±0.70(Predicted) |
| | Debio 0617B Usage And Synthesis |
| Uses | Debio 0617B, a multi-kinase inhibitor, reduces maintenance and self-renewal of primary human AML CD34+?stem/progenitor cells. Debio 0617B has a unique profile targeting key kinases upstream of STAT3/STAT5 signaling such as JAK, SRC, ABL, and class III/V receptor tyrosine kinases (TKs). Debio 0617B has documented efficacy in STAT3-driven solid tumors[1]. | | References | [1] Maximilien Murone,?et al. The Multi-kinase Inhibitor Debio 0617B Reduces Maintenance and Self-renewal of Primary Human AML CD34+?Stem/Progenitor Cells. Mol Cancer Ther.?2017 Aug;16(8):1497-1510. DOI:10.1158/1535-7163.MCT-16-0889 |
| | Debio 0617B Preparation Products And Raw materials |
|